Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 790
- Registration Number
- NCT02403323
- Locations
- 🇭🇺
Semmelweis Egyetem; Belgyogyaszati es Hematologiai Klinika, Budapest, Hungary
🇺🇸Valley Gastroenterology Consultants, Arcadia, California, United States
🇺🇸University of California San Diego Medical Center, La Jolla, California, United States
Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 353
- Registration Number
- NCT02402686
- Locations
- 🇭🇺
National Institute of Rheumatology and Physiotherapy; 4Th Rheumatology Department, Budapest, Hungary
🇭🇺Budai Irgalmasrendi Kórház KHT. II. Reumatológia, Budapest, Hungary
🇭🇺Szent Andras Reumakorhaz; Reumatologia, Heviz, Hungary
Phase IIIb Study to Evaluate the Safety and Tolerability of Herceptin SC With Perjeta and Docetaxel in Patients With HER2-positive Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 418
- Registration Number
- NCT02402712
- Locations
- 🇵🇱
MAGODENT Sp. z o.o., Warsaw, Poland
🇫🇷Pole Sante Republique; Pharmacie Oncologique, Clermont Ferrand, France
🇩🇪Studienzentrum Aschaffenburg, Aschaffenburg, Germany
A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Conditions
- Geographic Atrophy
- Interventions
- Other: No intervention
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 202
- Registration Number
- NCT02399072
- Locations
- 🇺🇸
Midwest Vision Research Foundation, Chesterfield, Missouri, United States
🇺🇸Retina Consultants of Houston, The Woodlands, Texas, United States
🇺🇸Retina Assoc of Cleveland Inc, Cleveland, Ohio, United States
Human Epidermal Growth Factor Receptor 2 (HER2) Positive Unresectable Locally Advanced or Metastatic Breast Cancer Disease Registry Study
- Conditions
- Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2024-02-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 311
- Registration Number
- NCT02393924
- Locations
- 🇬🇧
Kent & Canterbury Hospital, Canterbury, United Kingdom
🇬🇧Chesterfield Royal Hospital, Chesterfield, United Kingdom
🇬🇧Royal Cornwall Hospital; Dept of Clinical Oncology, Cornwall, United Kingdom
BELOVA Data Collection: Safety and Efficacy of Frontline Bevacizumab Treatment in Participants With Ovarian Cancer 70 Years and Older
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 76
- Registration Number
- NCT02393898
- Locations
- 🇧🇪
UZ Antwerpen, Edegem, Belgium
🇧🇪Sint Augustinus Wilrijk, Wilrijk, Belgium
🇧🇪UZ Leuven Gasthuisberg, Leuven, Belgium
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
- First Posted Date
- 2015-03-20
- Last Posted Date
- 2022-11-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1035
- Registration Number
- NCT02394028
- Locations
- 🇺🇸
Innovative Medical Research of South Florida, Aventura, Florida, United States
🇦🇹LKH - Universitätsklinikum der PMU Salzburg, Salzburg, Austria
🇭🇷Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia
A Study of Treatment With RO6864018 in Virologically Suppressed Participants With Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Hepatitis B, Chronic
- Interventions
- First Posted Date
- 2015-03-18
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 31
- Registration Number
- NCT02391805
- Locations
- 🇲🇾
University Malaya Medical Center, Kuala Lumpur, Malaysia
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)
- Conditions
- Pemphigus Vulgaris
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 135
- Registration Number
- NCT02383589
- Locations
- 🇹🇷
Gülhane Military Medical Academy in Ankara, Ankara, Turkey
🇪🇸Hospital de la Victoria, Malaga, Spain
🇺🇦Dnipropetrovsk State Medical Academy, Dnipropterovsk, Ukraine
Retrospective Data Collection: Post Study Treatment Anticancer Therapy From IMELDA MO22223
- Conditions
- Breast Cancer
- Interventions
- Other: No Intervention
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 185
- Registration Number
- NCT02383576
- Locations
- 🇪🇸
Hospital Virgen de los Lirios; Servicio de Oncologia, Alcoy, Alicante, Spain
🇪🇸Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, Spain
🇧🇷Hospital de Caridade de Ijui; Oncologia, Ijui, RS, Brazil